source
- BioNTech's mRNA cancer therapy fails to improve progression-free survival in head-neck cancer trialBioNTech reported that its experimental mRNA cancer immunotherapy, BNT 113, combined with Keytruda, did not meet the primary endpoint of progression-free survival in an interim analysis of a late-s…
- Roche expands obesity R&D footprint with Rona deal worth $1B+Roche has gained access to a genetic obesity approach from China's Rona Therapeutics for up to $100 million in upfront and near-term payments.